Frye Regional Medical Center has not ordered or used methylprednisolone, the drug associated with the recent fungal meningitis outbreak, from the New England Compounding Center (NECC).
October 22, the Food and Drug Administration (FDA) posted a list of healthcare facilities that received products shipped from the New England Compounding Center (NECC) on or after May 21, 2012. On its website, the FDA states "The lists were prepared based on information provided by NECC, and the FDA cannot vouch for completeness or accuracy of the lists." Although the hospital's name appears on the list as having received methylprednisolone, we have not purchased or received this drug from NECC. As of Monday night, the FDA removed the list from its website due to inaccuracies.
We have ordered and used cardioplegia, a drug used during heart surgery, from NECC during the time period currently being investigated by the Food and Drug Administration (FDA). The medication previously used by our hospital has not been linked to the outbreak of meningitis or other infections. As of October 4, 2012, we are no longer using this NECC product and have removed it from our pharmacy inventory.
Out of an abundance of caution, the FDA has asked all health care providers to notify patients who may have received this medication. We are identifying all patients who may be impacted and will notify them via US mail this week. Ensuring high-quality care and the safety of our patients is our highest priority and we will continue to monitor the situation closely.
Patients who may have received this drug can call our Patient Information Line at 855-827-2687. For more information about the outbreak, visit www.cdc.gov